• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

黏菌素 B 和多黏菌素 E 就疗效和肾毒性而言相当。

Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.

机构信息

Department of Infection Control of Hospital das Clínicas, Rua Dr. Ovídio Pires de Campos, São Paulo-SP 05403-010, Brazil.

出版信息

Diagn Microbiol Infect Dis. 2009 Dec;65(4):431-4. doi: 10.1016/j.diagmicrobio.2009.07.018. Epub 2009 Sep 3.

DOI:10.1016/j.diagmicrobio.2009.07.018
PMID:19733029
Abstract

We compared 41 patients who received colistimethate with 41 who received polymyxin B for the treatment of serious infections caused by carbapenem-resistant Acinetobacter spp. and found both polymyxins have similar efficacy and toxicity.

摘要

我们比较了 41 例接受黏菌素治疗和 41 例接受多黏菌素 B 治疗的碳青霉烯类耐药不动杆菌属引起的严重感染患者，发现两种黏菌素类药物具有相似的疗效和毒性。

相似文献

1
Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.黏菌素 B 和多黏菌素 E 就疗效和肾毒性而言相当。
Diagn Microbiol Infect Dis. 2009 Dec;65(4):431-4. doi: 10.1016/j.diagmicrobio.2009.07.018. Epub 2009 Sep 3.
2
Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.多黏菌素 B 或黏菌素甲磺酸钠治疗患者发生急性肾损伤的危险因素。
Int J Antimicrob Agents. 2014 Apr;43(4):349-52. doi: 10.1016/j.ijantimicag.2013.12.002. Epub 2013 Dec 15.
3
Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.黏菌素（多黏菌素甲磺酸钠）治疗泰国曼谷诗里拉吉医院耐多药铜绿假单胞菌和鲍曼不动杆菌所致感染的疗效与安全性
Int J Infect Dis. 2007 Sep;11(5):402-6. doi: 10.1016/j.ijid.2006.09.011. Epub 2007 Feb 8.
4
Colistin and polymyxin B in critical care.重症监护中的黏菌素和多黏菌素B
Crit Care Clin. 2008 Apr;24(2):377-91, x. doi: 10.1016/j.ccc.2007.12.003.
5
Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.联合使用黏菌素和利福平治疗耐碳青霉烯类鲍曼不动杆菌感染：临床疗效和不良事件
Clin Microbiol Infect. 2005 Aug;11(8):682-3. doi: 10.1111/j.1469-0691.2005.01198.x.
6
Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?多粘菌素的肾毒性：粘菌素甲磺酸钠与多粘菌素B之间有差异吗？
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02319-16. Print 2017 Mar.
7
Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.采用脑室注射硫酸多粘菌素B钠成功治疗耐碳青霉烯鲍曼不动杆菌引起的脑室炎。
Clin Infect Dis. 1999 Apr;28(4):916-7. doi: 10.1086/517243.
8
Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.多黏菌素与利福平联合治疗耐碳青霉烯类鲍曼不动杆菌引起的呼吸机相关性肺炎
Int J Antimicrob Agents. 2008 Sep;32(3):281-4. doi: 10.1016/j.ijantimicag.2008.04.013. Epub 2008 Jul 22.
9
Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.氨苄西林/舒巴坦与多黏菌素治疗耐碳青霉烯类不动杆菌属所致感染的比较
J Antimicrob Chemother. 2008 Jun;61(6):1369-75. doi: 10.1093/jac/dkn128. Epub 2008 Mar 25.
10
Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.多黏菌素B和多西环素在重症监护病房耐多药鲍曼不动杆菌感染患者中的应用。
Ann Pharmacother. 2006 Nov;40(11):1939-45. doi: 10.1345/aph.1H353. Epub 2006 Oct 3.

引用本文的文献

1
Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications.下一代治疗用拟肽药物的进展：策略、修饰及应用
Chem Rev. 2025 Aug 13;125(15):7099-7166. doi: 10.1021/acs.chemrev.4c00989. Epub 2025 Jul 23.
2
Biomarker-Driven Pharmacokinetics and Efficacy of Polymyxin B in Critically Ill Patients with XDR-GN Pneumonia.生物标志物驱动的多黏菌素B在XDR-GN肺炎重症患者中的药代动力学及疗效
Pharmaceuticals (Basel). 2025 Apr 17;18(4):586. doi: 10.3390/ph18040586.
3
Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China.
在中国，与血浆浓度优化的多粘菌素B治疗耐碳青霉烯革兰氏阴性菌感染相关的疗效和安全因素
Infect Drug Resist. 2024 Jul 16;17:3057-3071. doi: 10.2147/IDR.S468890. eCollection 2024.
4
Efficiency of polymyxin B treatment against nosocomial infection: a systematic review and meta-analysis.多粘菌素B治疗医院感染的疗效：一项系统评价和荟萃分析。
Front Med (Lausanne). 2024 May 28;11:1400757. doi: 10.3389/fmed.2024.1400757. eCollection 2024.
5
Recent Advances in the Development of Polymyxin Antibiotics: 2010-2023.近年来多黏菌素类抗生素的研究进展：2010-2023。
ACS Infect Dis. 2024 Apr 12;10(4):1056-1079. doi: 10.1021/acsinfecdis.3c00630. Epub 2024 Mar 12.
6
Semisynthetic polymyxins with potent antibacterial activity and reduced kidney cell toxicity.具有强效抗菌活性且肾细胞毒性降低的半合成多粘菌素。
RSC Med Chem. 2023 Oct 10;14(11):2417-2425. doi: 10.1039/d3md00456b. eCollection 2023 Nov 15.
7
Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections.多黏菌素 B 与黏菌素：在多重耐药革兰氏阴性菌感染中评估肾毒性和神经毒性及有效性的实用方法。
Indian J Pharmacol. 2023 Jul-Aug;55(4):229-236. doi: 10.4103/ijp.ijp_762_20.
8
Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant and .黏菌素与多黏菌素B治疗耐碳青霉烯类肠杆菌科细菌血流感染的比较 以及……（原文此处不完整）
Antibiotics (Basel). 2023 Aug 15;12(8):1317. doi: 10.3390/antibiotics12081317.
9
Does Monitoring Total and Free Polymyxin B1 Plasma Concentrations Predict Polymyxin B-Induced Nephrotoxicity? A Retrospective Study in Critically Ill Patients.监测多粘菌素B1血浆总浓度和游离浓度能否预测多粘菌素B引起的肾毒性？一项针对重症患者的回顾性研究。
Infect Dis Ther. 2022 Aug;11(4):1591-1608. doi: 10.1007/s40121-022-00655-3. Epub 2022 Jun 11.
10
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会 2022 年关于治疗产超广谱β-内酰胺酶肠杆菌科细菌（ESBL-E）、耐碳青霉烯肠杆菌科细菌（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的指导意见。
Clin Infect Dis. 2022 Aug 25;75(2):187-212. doi: 10.1093/cid/ciac268.